Netarsudil Mesylat/Latanoprost
Brand name: Rocklatan
Rank #238 of 500 drugs by total cost
$54.7M
Total Cost
103,171
Total Claims
$54.7M
Total Cost
2,397
Prescribers
$531
Cost per Claim
18,860
Beneficiaries
152,975
30-Day Fills
$23K
Avg Cost/Provider
43
Avg Claims/Provider
About Netarsudil Mesylat/Latanoprost
Netarsudil Mesylat/Latanoprost (sold as Rocklatan) was prescribed 103,171 times by 2,397 Medicare Part D providers in 2023, costing the program $54.7M. At $531 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 235 | Exenatide Microspheres (Bydureon Bcise) | $56.6M | 48,670 |
| 236 | Valsartan (Valsartan) | $56.4M | 1,481,937 |
| 237 | Benralizumab (Fasenra Pen) | $54.8M | 9,334 |
| 238 | Netarsudil Mesylat/Latanoprost (Rocklatan) | $54.7M | 103,171 |
| 239 | Amifampridine Phosphate (Firdapse) | $54.4M | 1,203 |
| 240 | Dapaglifloz Propaned/Metformin (Xigduo Xr) | $54.4M | 58,629 |
| 241 | Buspirone Hcl (Buspirone Hcl) | $53.7M | 2,868,147 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology